A Phase 3 interventional study of Dotinurad and Febuxostat in Gout, sponsored by Eisai Co., Ltd.. Completed at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dotinurad in Gout — 4 open to participants now, 4 under way, 1 of them phase 3. dotinurad · Gout.
Among the 10 studies testing dotinurad in Gout, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 5 in phase 3, and was the 5th registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →4 of the 10 studies testing dotinurad in Gout are open now, in 4 countries. Recruiting first, the newest first:
Crystalys Therapeutics · Sites in United States
Ages 18–75
Crystalys Therapeutics · Sites in United States, Poland, Spain
Ages 18–75
Saga University · Sites in Japan
Ages 20+
First Affiliated Hospital of Wenzhou Medical University
Ages 18–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 5 · Phase 4 2
First in 2016; this study’s year is marked. 1 started in 2021.
This study's enrollment of 451 is above the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 202 across the 10 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 7 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 1 study filed under Gout — fewer than ten, so there is no comparison to draw.
4 of the studies testing dotinurad in Gout that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089875Phase 3Crystalys TherapeuticsA Study of Dotinurad Versus Allopurinol in Participants With Gout | 2027-11-29 |
| NCT07535034Crystalys TherapeuticsA Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | 2027-07 |
| NCT07661030First Affiliated Hospital of Wenzhou Medical UniversityThe Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time | 2027-07-30 |
| NCT06834230Saga UniversityEffect of Dotinurad in Hyperuricemia With Hypertension | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies testing dotinurad in Gout, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to febuxostat 40 mg on the percentage of participants achieving a serum uric acid (SUA) level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 in Chinese participants with gout.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one dotinurad 1 mg tablet and one febuxostat 20 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then one dotinurad 2 mg tablet and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two dotinurad 2 mg tablets and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
Drug: Dotinurad · Other: Febuxostat Matched Placebo
Participants will receive one febuxostat 20 mg tablet and one dotinurad 1 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then two febuxostat 20 mg tablets and one dotinurad 2 mg matched placebo tablet, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two febuxostat 20 mg tablets and two dotinurad 2 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).
Drug: Febuxostat · Other: Dotinurad Matched Placebo
Dotinurad oral tablets.
Also known as: FYU-981
Febuxostat oral tablets.
Dotinurad matched placebo oral tablets.
Febuxostat matched placebo oral tablets.
Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)
Percentage of participants with SUA level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 was reported. In case the SUA level was missing, this data was compensated by the last observation carried forward (LOCF) method.
Time frame: At Week 24
Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF)
Percentage of participants with SUA level \<=6.0 mg/dL at Week 12 was reported. In case the SUA level was missing, this data was compensated by the LOCF method.
Time frame: At Week 12
Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24
Percentage of participants with SUA level \<=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 was reported. Data was reported for observed participants at specified visits.
Time frame: At Weeks 4, 8, 12, 16, 20 and 24
Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24
Mean percent reduction from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Mean Change From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24
Mean change from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Mean SUA Level at Baseline, Weeks 4, 8, 12, 16, 20 and 24
Mean SUA level at Baseline, Weeks 4, 8, 12, 16, 20 and 24 was reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Participants took part in the study at 30 investigative sites in China from 21 December 2021 to 14 June 2023.
| Milestone | Febuxostat | Dotinurad |
|---|---|---|
| Started | 226 | 225 |
| Safety analysis set | 225 | 223 |
| Full analysis set | 220 | 221 |
| Completed | 197 | 195 |
| Not completed | 29 | 30 |
| Withdrew: Randomized but not treated | 1 | 2 |
| Withdrew: Other | 5 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Serum uric acid (sua) level of <=2.0 milligram per deciliter (mg/dl) for 2 consecutive visits | 0 | 1 |
| Withdrew: Use of prohibited concomitant drug | 1 | 1 |
| Withdrew: Inadequate therapeutic effect or progression of disease | 1 | 0 |
| Withdrew: Adverse event | 10 | 6 |
| Withdrew: Participant choice | 5 | 10 |
| Withdrew: Withdrawal of consent | 5 | 4 |
Percentage of participants with SUA level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 was reported. In case the SUA level was missing, this data was compensated by the last observation carried forward (LOCF) method.
| percentage of participants | Febuxostat | Dotinurad |
|---|---|---|
| Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF) | 38.1 (31.6 to 44.5) | 73.6 (67.8 to 79.5) |
Percentage of participants with SUA level \<=6.0 mg/dL at Week 12 was reported. In case the SUA level was missing, this data was compensated by the LOCF method.
| percentage of participants | Febuxostat | Dotinurad |
|---|---|---|
| Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF) | 50.5 (43.8 to 57.1) | 55.5 (48.9 to 62.0) |
Percentage of participants with SUA level \<=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 was reported. Data was reported for observed participants at specified visits.
| percentage of participants | Febuxostat | Dotinurad |
|---|---|---|
| Week 4 | 26.3 | 27.6 |
| Week 8 | 55.6 | 62.7 |
| Wee 12 | 52.8 | 56.9 |
| Week 16 | 48.7 | 84.7 |
| Week 20 | 53.7 | 83.0 |
| Week 24 | 40.2 | 78.1 |
Mean percent reduction from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.
| Percent change in SUA level | Febuxostat | Dotinurad |
|---|---|---|
| Percent Reduction from Baseline at Week 4 | 26.43 ± 13.200 | 27.43 ± 14.754 |
| Percent Reduction from Baseline at Week 8 | 37.06 ± 14.018 | 39.10 ± 18.931 |
| Percent Reduction from Baseline at Week 12 | 36.06 ± 15.383 | 38.62 ± 17.305 |
| Percent Reduction from Baseline at Week 16 | 35.13 ± 16.016 | 51.47 ± 18.542 |
| Percent Reduction from Baseline at Week 20 | 35.71 ± 15.728 | 50.22 ± 20.714 |
| Percent Reduction from Baseline at Week 24 | 32.28 ± 16.907 | 48.07 ± 23.243 |
Mean change from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.
| mg/dL | Febuxostat | Dotinurad |
|---|---|---|
| Change from Baseline at Week 4 | -2.60 ± 1.457 | -2.70 ± 1.508 |
| Change from Baseline at Week 8 | -3.62 ± 1.597 | -3.80 ± 1.973 |
| Change from Baseline at Week 12 | -3.52 ± 1.691 | -3.78 ± 1.817 |
| Change from Baseline at Week 16 | -3.44 ± 1.731 | -5.05 ± 2.078 |
| Change from Baseline at Week 20 | -3.52 ± 1.757 | -4.92 ± 2.201 |
| Change from Baseline at Week 24 | -3.20 ± 1.800 | -4.71 ± 2.415 |
Mean SUA level at Baseline, Weeks 4, 8, 12, 16, 20 and 24 was reported.
| mg/dL | Febuxostat | Dotinurad |
|---|---|---|
| Baseline | 9.65 ± 1.426 | 9.67 ± 1.451 |
| Week 4 | 7.07 ± 1.432 | 6.93 ± 1.447 |
| Week 8 | 6.01 ± 1.372 | 5.80 ± 1.857 |
| Week 12 | 6.12 ± 1.546 | 5.88 ± 1.708 |
| Week 16 | 6.24 ± 1.605 | 4.65 ± 1.776 |
| Week 20 | 6.14 ± 1.467 | 4.76 ± 1.900 |
| Week 24 | 6.49 ± 1.575 | 5.00 ± 2.296 |
Collected over From first dose of study drug up to Week 24. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat | 0/225 (0%) | 4/225 (1.8%) | 203/225 (90.2%) |
| Dotinurad | 0/223 (0%) | 3/223 (1.3%) | 201/223 (90.1%) |
| Event | Febuxostat | Dotinurad |
|---|---|---|
| HaemorrhoidsGastrointestinal disorders | 0/225 | 1/223 |
| Inguinal herniaGastrointestinal disorders | 0/225 | 1/223 |
| Ankle fractureInjury, poisoning and procedural complications | 0/225 | 1/223 |
| Joint dislocationInjury, poisoning and procedural complications | 0/225 | 1/223 |
| Ligament injuryInjury, poisoning and procedural complications | 0/225 | 1/223 |
| CataractEye disorders | 1/225 | 0/223 |
| Meniscus injuryInjury, poisoning and procedural complications | 1/225 | 0/223 |
| Neoplasm skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/225 | 0/223 |
| Glomerulonephritis membranousRenal and urinary disorders | 1/225 | 0/223 |
| Event | Febuxostat | Dotinurad |
|---|---|---|
| Gouty arthritisMusculoskeletal and connective tissue disorders | 78/225 | 97/223 |
| COVID-19Infections and infestations | 57/225 | 57/223 |
| Alanine aminotransferase increasedInvestigations | 28/225 | 18/223 |
| Hepatic function abnormalHepatobiliary disorders | 18/225 | 24/223 |
| Upper respiratory tract infectionInfections and infestations | 22/225 | 13/223 |
| Alpha 1 microglobulin increasedInvestigations | 19/225 | 12/223 |
| SARS-CoV-2 test positiveInvestigations | 8/225 | 17/223 |
| NephrolithiasisRenal and urinary disorders | 17/225 | 14/223 |
| HyperlipidaemiaMetabolism and nutrition disorders | 13/225 | 16/223 |
| Blood creatine phosphokinase increasedInvestigations | 15/225 | 8/223 |
Full Analysis Set was the group of randomized participants who received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement.
| Age, Continuous(years) | Febuxostat | Dotinurad | Total |
|---|---|---|---|
| Mean | 39.2 ± 10.98 | 38.9 ± 11.56 | 39.1 ± 11.26 |
| Sex: Female, Male(Participants) | Febuxostat | Dotinurad | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 215 | 218 | 433 |
| Ethnicity (NIH/OMB)(Participants) | Febuxostat | Dotinurad | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 220 | 221 | 441 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Febuxostat | Dotinurad | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 220 | 221 | 441 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Ran from Dec 2021 to primary completion in Jun 2023, 17 months.
Results were first posted in Jul 2025, 2 years 1 month after primary completion.
Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dotinurad